[Post-diarrhea hemolytic-uremic syndrome: clinical aspects]

Area of Science:

• Pediatric Nephrology
• Infectious Diseases
• Gastroenterology

Context:

• Diarrhea-associated hemolytic uremic syndrome (D+HUS) affects approximately 100 children annually in France, primarily under three years old.
• Verotoxin-producing Escherichia coli (VTEC), particularly the O157:H7 serotype, is implicated in about 85% of D+HUS cases.
• The condition follows a prodromal gastroenteritis, characterized by sudden onset of hemolytic anemia, thrombocytopenia, and acute renal insufficiency.

Purpose:

• To summarize the clinical presentation, outcomes, and public health implications of diarrhea-associated hemolytic uremic syndrome (D+HUS) in children.
• To highlight the role of VTEC in D+HUS pathogenesis and discuss preventive strategies.
• To identify predictive factors for poor renal outcomes in acute D+HUS.

Summary:

• D+HUS presents with hemolytic anemia, thrombocytopenia, and renal insufficiency, often preceded by bloody diarrhea.
• Extraintestinal manifestations include severe colitis, pancreatitis, and central nervous system involvement, impacting prognosis.
• While mortality is below 5% with supportive care, long-term sequelae such as chronic kidney disease, proteinuria, and hypertension affect at least one-third of survivors.

Impact:

• Early recognition and management of D+HUS are crucial for improving patient outcomes and reducing mortality.
• Understanding VTEC's role underscores the importance of public health measures for preventing E. coli infections.
• Identifying predictive factors for renal damage can guide intensive monitoring and treatment strategies for high-risk pediatric patients.